Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira®
- Friday, December 6, 2019, 7:20
- Environment
- Add a comment
BRUSSELS, Dec. 6, 2019 /PRNewswire/ — Regulated Information – Inside Information – UCB, a global biopharmaceutical company, today announced positive results from the Phase 3 active-controlled BE SURE study. BE SURE compared the investigational IL-17A and IL-17F inhibitor bimekizumab to…
About the Author
adminasapcorp has written 39417 stories on this site.